

Cenegermin for the treatment of moderate or severe neurotrophic keratopathy: results from a prospective, phase IV, open-label study in China

Suxia Li,^a Jianjiang Xu,^b Jin Yuan,^c Zhiqiang Pan,^d Giacomo Siri,^e Scott G. Hauswirth,^f Flavio Mantelli,^g Weiyun Shi^h

^aEye Hospital of Shandong First Medical University, Jinan, Shandong, China; ^bCorneal diseases department, Zhongshan Ophthalmic Center, Sun Yat-sen University, Guangzhou, Guangdong, China; ^cOphthalmology Department, Beijing Tongren Hospital, Capital Medical University, Beijing, China; ^dOphthalmology Department, Beijing Tongren Hospital, Capital Medical University, Beijing, China; ^eDompé farmaceutici S.p.A., Milan, Italy; ^fDompé farmaceutici S.p.A., Milan, Italy; ^gDompé farmaceutici S.p.A., Milan, Italy; ^hEye Hospital of Shandong First Medical University, Jinan, Shandong, China

Corresponding author: Weiyun Shi, Eye Hospital of Shandong First Medical University, Jinan, Shandong, China; email: weiyunshi@163.com

Supplementary Figure 1. Study design

